Ann Barbier says adios to Agios as she takes up Translate Bio role

Spotlight
Barbier leaves Agios just a few months after it and Celgene gained FDA approval for a new cancer medication.

Agios and Shire vet Ann Barbier, M.D., Ph.D., has become the new chief medical officer at RNA biotech Translate Bio.

Barbier becomes the new CMO at a time of burgeoning hope in RNA research, coming a week after RNAi pioneer Alnylam posted a set of stellar results for its patisiran in hereditary TTR amyloidosis, and coming off the back of a number of setbacks in the area over the past few years.

RELATED: Arrowhead snaps after trial hold as it targets major layoffs, ditches programs

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Under her new role, Barbier will be responsible for leading all clinical research and development, medical affairs and related functions at the Cambridge, Massachusetts-based biotech.

This includes its early-stage work on cystic fibrosis, as well as ornithine transcarbamylase (OTC) deficiency, which are both preclinical, although its CF program is slated for human trials from next year.

She comes direct from Celgene-backed Agios, a Fierce 15 winner in 2009, where she was VP of clinical development in rare genetic diseases, having also worked in genetics diseases and pharmaceuticals at Shire.

RELATED: Celgene and Agios win FDA approval for targeted AML drug Idhifa

“We are thrilled to welcome Barbier to Translate Bio,” said Ronald Renaud, CEO at Translate Bio.

“She is a proven leader with a track record of advancing clinical research through all phases of development. Additionally, Barbier’s rare disease expertise and extensive experience engaging regulatory agencies make her an invaluable asset as we look ahead to initiating our first clinical study in cystic fibrosis in early 2018.”

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.